Table 5 GO categories of SUMO targeting genes during KSHV reactivation
SUMO-1 | SUMO-2/3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
0 h | 12 h | 0 h | 12 h | |||||||
Pathway category | Genes in category | Genes identified | p-value | Genes identified | p-value | Genes identified | p-value | Genes identified | p-value | |
Pathogen-influenced signaling | Virus entry via endocytic pathways | 99 | 14 | 2.59E-01 | 16 | 8.71E-02 | 13 | 3.35E-01 | 31 | 1.41E-03 |
Cellular immune response | Antigen presentation pathway | 40 | 8 | 9.77E-02 | 5 | 5.02E-01 | 8 | 8.71E-02 | 14 | 1.26E-02 |
CD40 signaling | 70 | 11 | 1.87E-01 | 12 | 8.91E-02 | 11 | 1.67E-01 | 23 | 2.82E-03 | |
HMGB1 signaling | 99 | 15 | 2.19E-01 | 18 | 3.89E-02 | 13 | 3.96E-01 | 25 | 9.33E-02 | |
IL-10 signaling | 78 | 13 | 9.55E-02 | 14 | 4.07E-02 | 10 | 3.58E-01 | 19 | 9.55E-02 | |
IL-15 signaling | 67 | 8 | 5.43E-01 | 12 | 7.41E-02 | 8 | 5.15E-01 | 20 | 1.86E-02 | |
IL-3 signaling | 74 | 11 | 3.11E-01 | 12 | 1.74E-01 | 10 | 4.11E-01 | 23 | 1.41E-02 | |
IL-8 signaling | 205 | 29 | 1.52E-01 | 28 | 1.61E-01 | 29 | 1.25E-01 | 48 | 4.68E-02 | |
NF-κB activation by viruses | 82 | − | − | 12 | 1.99E-01 | − | − | 23 | 2.00E-02 | |
p38 MAPK signaling | 117 | 22 | 4.47E-02 | 18 | 2.10E-01 | 17 | 3.10E-01 | 26 | 3.80E-01 | |
Toll-like receptor signaling | 62 | 14 | 1.05E-02 | 9 | 2.65E-01 | − | − | 17 | 5.75E-02 | |
Cytokine signaling | IL-17A signaling in airway cells | 72 | 9 | 4.33E-01 | 12 | 8.91E-02 | 10 | 2.72E-01 | 21 | 1.35E-02 |
Prolactin signaling | 80 | 10 | 4.78E-01 | 13 | 1.21E-01 | − | − | 22 | 3.72E-02 | |
Cancer | Glioma signaling | 112 | 17 | 1.03E-01 | 14 | 3.01E-01 | − | − | 29 | 1.55E-02 |
p53 signaling | 96 | 18 | 5.13E-02 | 16 | 1.17E-01 | 16 | 1.24E-01 | 32 | 1.48E-03 | |
Small cell lung cancer signaling | 89 | 13 | 1.24E-01 | 13 | 1.02E-01 | 13 | 1.08E-01 | 27 | 6.03E-04 | |
Sonic hedgehog signaling | 33 | 6 | 1.65E-01 | 9 | 7.24E-03 | 5 | 3.03E-01 | − | − | |
Cellular growth, proliferation and development | Cleavage and polyadenylation of Pre-mRNA | 12 | 5 | 1.32E-02 | 4 | 5.37E-02 | 3 | 1.87E-01 | 5 | 8.32E-02 |
EGF signaling | 62 | 11 | 1.02E-01 | 8 | 4.05E-01 | − | − | 21 | 2.88E-03 | |
FAK signaling | 101 | − | − | 15 | 1.15E-01 | 12 | 4.06E-01 | 27 | 1.32E-02 | |
JAK/Stat signaling | 70 | 13 | 8.71E-02 | 13 | 7.08E-02 | 10 | 3.40E-01 | 26 | 5.37E-04 | |
Oncostatin M signaling | 35 | 5 | 4.55E-01 | 5 | 4.26E-01 | − | − | 12 | 3.55E-02 | |
PDGF signaling | 85 | 12 | 2.92E-01 | 12 | 2.54E-01 | − | − | 25 | 1.07E-02 | |
Thrombopoietin signaling | 63 | 8 | 4.22E-01 | 10 | 1.45E-01 | − | − | 17 | 4.90E-02 | |
VEGF signaling | 103 | 17 | 7.59E-02 | 19 | 1.66E-02 | 13 | 3.66E-01 | 25 | 7.59E-02 | |
Cell cycle regulation | Cyclins and cell cycle regulation | 89 | 14 | 1.38E-01 | 11 | 4.05E-01 | 15 | 6.92E-02 | 24 | 2.75E-02 |
GADD45 signaling | 22 | 4 | 2.26E-01 | 3 | 4.33E-01 | 5 | 8.32E-02 | 9 | 8.51E-03 | |
Mitotic roles of polo-like kinase | 70 | 11 | 2.46E-01 | 11 | 2.14E-01 | 14 | 3.89E-02 | 18 | 1.39E-01 | |
Growth factor signaling | ErbB2-ErbB3 signaling | 60 | − | − | 11 | 9.55E-02 | − | − | 19 | 1.82E-02 |
Apoptosis | April mediated signaling | 43 | 8 | 1.10E-01 | 6 | 3.40E-01 | 8 | 1.00E-01 | 13 | 3.72E-02 |
Aryl hydrocarbon receptor signaling | 161 | 24 | 8.51E-02 | 19 | 3.81E-01 | 23 | 1.07E-01 | 40 | 1.48E-02 | |
Myc mediated apoptosis signaling | 60 | 10 | 2.13E-01 | 10 | 1.85E-01 | 9 | 3.10E-01 | 20 | 1.05E-02 | |
Cellular stress and injury | Endoplasmic reticulum stress pathway | 18 | 7 | 5.25E-03 | 5 | 6.61E-02 | 5 | 6.76E-02 | 7 | 6.03E-02 |
Disease-specific pathways | Parkinson’s signaling | 16 | 3 | 3.44E-01 | 4 | 1.31E-01 | 5 | 4.27E-02 | 4 | 4.32E-01 |
Neurotransmitters and other nervous system signaling | Cholecystokinin/gastrin-mediated signaling | 106 | 21 | 1.82E-02 | 13 | 5.05E-01 | 15 | 2.94E-01 | 24 | 2.59E-01 |